Goldman Sachs Lowers Estimates on Illumina, But Favors MiSeq Growth Over PGM | GenomeWeb

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Citing a market shift toward the MiSeq desktop sequencer, Goldman Sachs today revised its earnings per share estimates for Illumina.

For 2011, the investment bank maintained EPS estimates at $1.55, but lowered its forecast for 2012 to $2.04 from $2.08, and its estimate for 2013 to $2.64 from $2.70. It also cut its 12-month share price target to $83 from $84.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.